Adverse Family Outcomes in Children With B-Cell Acute Lymphoblastic Leukemia From the Multicenter Trial Children's Oncology Group AALL0932.

What was studied

This study sat inside a randomized trial of children with B-cell acute lymphoblastic leukemia. The trial compared drug plans. One gave drugs every 4 weeks and one every 12 weeks. Parents filled in surveys at several points after diagnosis. The surveys asked about household changes, costs, family life and how vulnerable the child seemed. Of 555 people with completed evaluations, 420 were randomized.

What they found

Family burdens showed up early. Reports of household changes rose over time. Reports of high costs were lower at the fourth survey. Reports of unhealthy family functioning rose. So did reports that the child was vulnerable. The 4-week plan was linked to more reports of costs of at least $100. Other outcomes were similar between the plans.

What it means for patients

The authors say family burdens develop early. They say a less frequent drug plan may lower costs but not other burdens. They say families need support early and through treatment.

Why it is not certain yet

Only families with an English-speaking parent took part. Parents reported all outcomes themselves. The fifth survey was done only in boys. Only the cost result differed between the plans.

Source

Adverse Family Outcomes in Children With B-Cell Acute Lymphoblastic Leukemia From the Multicenter Trial Children's Oncology Group AALL0932.

We restate facts from the source record in our own words. The original wording belongs to its publisher.